Industry Overview

Coronary stent market was valued at $10.9 billion in 2025 and is projected to reach $17.8 billion by 2035, growing at a CAGR of 5.1% during the forecast Period (2026-2035). The market is driven by the increasing prevalence of cardiovascular diseases (CVDs), aging populations, lifestyle factors like obesity and diabetes, and rapid advancements in stent technology, such as drug-eluting and bioresorbable stents. Key factors influencing the market include technological innovation in design and materials, high demand for minimally invasive procedures, and a competitive landscape involving strategic partnerships and regulatory approvals. The success of stenting is determined by factors like deliverability, prevention of restenosis (re-narrowing), and stent thrombosis (clotting), with outcomes heavily dependent on stent design, material, and post-procedure patient care, particularly adherence to antiplatelet therapy.

Market Dynamics

Rising Prevalence of Cardiovascular Disease and Demographic Risk Factors

One of the most significant drivers behind the growth of the coronary stent market is the increasing global burden of coronary artery disease (CAD) and other cardiovascular conditions. As populations age, the incidence of CAD, hypertension, diabetes, and obesity is rising, which increases the demand for interventional procedures such as percutaneous coronary interventions (PCI) that rely on stents.  In addition, the geriatric population is growing rapidly worldwide, creating a larger patient pool more susceptible to heart disease. Older patients often require stenting because they may not be ideal candidates for open-heart surgery.

Technological Advancements and Innovation In Stent Design

Technological progress in stent systems is fueling adoption. Innovations such as drug-eluting stents (DES), bioresorbable (or bioabsorbable) stents, polymer-free coatings, and dual?therapy scaffolds are improving clinical outcomes by lowering restenosis, enhancing biocompatibility, and reducing long-term risks.  For instance, bioresorbable stents dissolve after fulfilling their purpose, minimizing the risk of late thrombosis and potentially reducing the need for prolonged antiplatelet therapy.  These technology-driven improvements make stent procedures safer and more effective, encouraging more clinicians to choose stenting for coronary interventions.

Increasing Demand for Minimally Invasive Procedures and Supportive Reimbursement Policies

There is a growing preference among both patients and cardiologists for minimally invasive interventions over more invasive surgical approaches. Coronary stent implantation through PCI is less traumatic, offers shorter hospital stays, and has faster recovery compared to open-heart surgery, making it highly attractive.  Moreover, in many regions, favorable reimbursement policies bolster the adoption of advanced stents. Pro-reimbursement environments make it easier for patients to access next-generation stents (e.g., DES, bioresorbable), and payers are more willing to cover these high-value, outcome?oriented devices.

Market Segmentation

• Based on the mode of delivery, the market is segmented into balloon-expandable stents
• self-expanding stents and others.
• Based on the product, the market is segmented into bare-metal stents, drug-eluting stents, and bioabsorbable stents.

Segment to Grow at a Considerable Market Share

Among all segments of the global coronary stent market, drug-eluting stents (DES) are projected to lead in terms of market share and growth. DES dominate due to their ability to significantly reduce the risk of restenosis and the need for repeat interventions compared to bare-metal stents and bioabsorbable stents. Advances in DES technology, such as thinner struts, improved polymer coatings, and next-generation drug formulations, have enhanced safety and efficacy, making them the preferred choice for interventional cardiologists worldwide. Moreover, balloon-expandable DES are widely used in percutaneous coronary interventions because of their precise deployment and superior clinical outcomes. The combination of high clinical adoption, technological innovation, and broad availability positions Drug-Eluting Stents as the largest and most influential segment driving the global coronary stent market over the forecast period.

Regional Outlook

The global coronary stent market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

North America is the dominant region in the global coronary stent market, and the US dominates the global coronary stent market, holding the largest share due to its highly developed healthcare infrastructure, advanced medical technology adoption, and strong presence of leading cardiovascular device manufacturers. The country has witnessed significant growth in the prevalence of cardiovascular diseases (CVDs), particularly coronary artery disease, which has driven the demand for stenting procedures as a standard treatment for restoring blood flow in blocked arteries. The adoption of drug-eluting stents (DES) over bare-metal stents (BMS) is particularly high in the US, owing to clinical evidence supporting their efficacy in reducing restenosis rates and improving patient outcomes. Additionally, reimbursement policies and government initiatives to promote advanced cardiovascular care have further bolstered the market, making coronary stents more accessible across hospitals and cardiac care centers.

The US also benefits from a robust research and development ecosystem, with several key players such as Abbott Laboratories, Boston Scientific Corp., and Medtronic leading innovations in stent design, materials, and delivery mechanisms. These companies invest heavily in product development, focusing on bioabsorbable stents and next-generation DES to enhance patient safety and long-term efficacy. Furthermore, the country’s high per capita healthcare spending, coupled with an increasing aging population prone to heart-related ailments, ensures sustained demand for coronary stenting procedures. Strong regulatory frameworks, advanced clinical infrastructure, and ongoing clinical trials contribute to maintaining the US as the global leader in the coronary stent market, driving both market growth and technological advancements that influence trends globally.

Market Players Outlook

The major companies operating in the global coronary stent market include Abbott Laboratories, B. Braun Melsungen AG, Boston Scientific Corp., Medtronic Plc, Terumo Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In October 2025, Abbott launched the XIENCE Sierra coronary stent system in India, following its regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) in February. This latest generation of the XIENCE family is designed for treating narrowed coronary arteries due to coronary artery disease, as noted by the US FDA.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global coronary stent market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.